Skye Bioscience (SKYE) Proxy filing summary

Executive summary

• Advanced nimacimab to proof-of-concept in obesity, showing additional weight loss and improved body composition when combined with semaglutide, with a favorable safety profile over 52 weeks.

• Initiated higher-dose expansion of CBeyond study to optimize exposure and safety, with plans to incorporate FDA feedback into Phase 2b design and explore advanced subcutaneous delivery technologies.

• Early proof-of-concept achieved for antibody-peptide conjugate program, broadening the metabolic disease platform.

• Maintained focus on capital discipline and operational alignment with key development milestones.

• Forward-looking statements highlight execution priorities for 2026, including additional data readouts and platform expansion.

Voting matters and shareholder proposals

• Election of six directors for one-year terms expiring at the 2027 annual meeting.

• Ratification of CBIZ CPAs P.C. as independent registered public accounting firm for 2026.

• Approval of amendment to increase authorized common stock from 100,000,000 to 300,000,000 shares.

• Advisory vote on executive compensation (say-on-pay).

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of six members, majority independent per Nasdaq standards.

• Chairman and CEO roles are separated for balanced oversight.

• Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.

• Anti-hedging and compensation recoupment (clawback) policies in place.

• Code of Business Conduct and Ethics and Corporate Governance Guidelines adopted.